Information from Industry - Sponsored Supplement

A Second-Line Treatment Option for Hepatocellular Carcinoma

Developed under the direction and sponsorship of Exelixis, Inc. This content was peer reviewed by Federal Practitioner.

 

In this special supplement to Federal Practitioner, Dr. Binu John of the University of Miami discusses the challenges and treatment options for Hepatocellular Carcinoma (HCC), a common type of liver cancer, with a focus on patients with Child-Pugh B cirrhosis. It highlights the increasing incidence of liver cancer, especially in the context of cirrhosis caused by various factors, and the significance of early diagnosis and curative treatment in improving survival rates.

 

Click here to Read More

 

 

 

 

 

Recommended Reading

Stripped privileges: An alarming precedent for community oncologists?
Federal Practitioner
Does diabetes affect colorectal cancer outcomes?
Federal Practitioner
ACS expands lung cancer screening eligibility
Federal Practitioner
This tool can predict recurrence in rectal cancer watchful waiting
Federal Practitioner
Can thermal biofeedback reduce pain and anxiety?
Federal Practitioner
Gut microbiome variations may be predictive of precancerous colonic lesions, CRC
Federal Practitioner
Older adults at risk from inappropriate prescribing
Federal Practitioner
Strength training promotes knee health, lowers OA risk
Federal Practitioner
Be advised: Thyroid hormones may increase risk of cognitive disorders in older adults
Federal Practitioner
Insulin appears less heat-sensitive than previously thought
Federal Practitioner